Another biotech scoops up asset from China-based Keymed and nabs $180Mnews2025-01-10T12:19:00+00:00January 10th, 2025|Endpoints News|
Exclusive: Avenzo picks up another ADC, this time with multi-partnered DualityBionews2025-01-07T12:00:59+00:00January 7th, 2025|Endpoints News|
WuXi Biologics to sell Irish vaccine site to Merck for $500Mnews2025-01-06T16:58:02+00:00January 6th, 2025|Endpoints News|
WuXi AppTec sells cell and gene therapy business to investornews2024-12-26T16:25:08+00:00December 26th, 2024|Endpoints News|
Biosecure Act influence still felt even as China bill stallsnews2024-12-18T19:41:08+00:00December 18th, 2024|Endpoints News|
Merck’s long-awaited obesity move is an oral GLP-1 from Chinanews2024-12-18T15:18:50+00:00December 18th, 2024|Endpoints News|
The Endpoints 100 Survey: Biotech industry braces for Trump 2.0news2024-12-11T12:00:55+00:00December 11th, 2024|Endpoints News|
Exclusive: Angitia, a Bain-backed musculoskeletal biotech, raises $120M for trio of clinical-stage biologicsnews2024-12-11T12:00:35+00:00December 11th, 2024|Endpoints News|
Biosecure bill is left out of end-of-year defense packagenews2024-12-08T02:00:38+00:00December 8th, 2024|Endpoints News|
GSK makes another ADC deal, this time with BioNTech’s partner DualityBionews2024-12-04T08:28:36+00:00December 4th, 2024|Endpoints News|
